Simplify Asset Management Inc. Sells 270,600 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Simplify Asset Management Inc. trimmed its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 77.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 80,714 shares of the company’s stock after selling 270,600 shares during the quarter. Simplify Asset Management Inc. owned 0.15% of Fulcrum Therapeutics worth $379,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of FULC. State Street Corp boosted its holdings in Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after purchasing an additional 638,955 shares during the period. Geode Capital Management LLC lifted its stake in shares of Fulcrum Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock valued at $4,716,000 after buying an additional 13,485 shares during the period. Braidwell LP acquired a new stake in Fulcrum Therapeutics during the third quarter worth about $3,817,000. Charles Schwab Investment Management Inc. increased its stake in Fulcrum Therapeutics by 223.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock valued at $2,032,000 after acquiring an additional 393,202 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Fulcrum Therapeutics by 176.8% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company’s stock valued at $1,728,000 after acquiring an additional 234,810 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Fulcrum Therapeutics has a consensus rating of “Hold” and a consensus price target of $8.63.

Fulcrum Therapeutics Trading Up 4.3 %

Shares of FULC opened at $3.15 on Friday. The stock has a market cap of $170.03 million, a PE ratio of -10.16 and a beta of 2.20. Fulcrum Therapeutics, Inc. has a 1 year low of $2.78 and a 1 year high of $10.13. The stock has a 50 day simple moving average of $3.62 and a 200-day simple moving average of $3.91.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). On average, sell-side analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.